HM17321
- Hanmi Licenses Muscle-Preserving Obesity Candidate to Genentech for Up to $2.3 Billion
Hanmi Pharmaceutical licensed obesity drug candidate HM17321 to Roche's Genentech for up to $2.3 billion, including a $190 million upfront payment.
Hanmi Pharmaceutical licensed obesity drug candidate HM17321 to Roche's Genentech for up to $2.3 billion, including a $190 million upfront payment.
